Sentence examples for vector applications from inspiring English sources

However, traditional vector applications would easily overflow the limited memory of a single integrated node.

However, vector toxicity and transgene silencing have created significant barriers to vector applications to the brain.

Given these problems with safety and efficacy, gene therapy trials have shifted from "single-gene" diseases to conditions like cancer, cardiovascular disease, and rheumatoid arthritis, where vector applications are more local and transient (Branca 2005).

Here, we synthesize our previously reported monomer N-ethyl pyrrolidine methacrylamide (EPA) and evaluate its effectiveness in gene vector applications when copolymerized with 1-vinylimidazole (VI).

Furthermore, a major proportion of the human population has antibodies against AAVs and adenovirus from previous infections, thus limiting the number of viral vector applications that can be made in a patient setting (Chirmule et al, 1999).

Moreover, differentiated keratinocytes in organotypic airlifted three-dimensional cultures were transduced following topical vector application.

To study HSV-1 amplicon vector-mediated tk gene expression in vivo, subcutaneous Gli36ΔEGFR tumors, vector application and PET imaging were performed as described previously [6], [34].

Analysis of luciferase gene expression was performed on an IVIS200 optical imaging system (Xenogen Corp., USA) at multiple time points after vector application (48 hours, 2 19 days).

Rabbits were subjected to fluorescence imaging every 12 h for the first 3 days after AAV5 vector application, and thereafter once a week until euthanasia.

Multi-modal in vivo imaging is being employed for tumor localization (MRI), assessment of viable target tissue for vector application (FDG-/FLT-PET FDG-/FLT-PET FDG-/FLT-PETgulandd tissue-dose of vector-mediassessmentexpressiof (FHBG-PEtheBLI).

To avoid vector application into necrotic tumor, viable tumor tissue was visualized by means of [18F]FDG- or [18F]FLT-PET after intravenous (i.v.; tail vein) administration of no-carrier-added [18F]FDG or [18F]FLT (no-carrier-added) into experimental animals with doses ranging between 200 300 µCi/mouse.